TR200100254T2 - Eriyebilir ve bakterilerle ayrışabilir bir gen iletim taşıyıcısı olarak poly-l-lysine benzeri bir poliyester. - Google Patents

Eriyebilir ve bakterilerle ayrışabilir bir gen iletim taşıyıcısı olarak poly-l-lysine benzeri bir poliyester.

Info

Publication number
TR200100254T2
TR200100254T2 TR2001/00254T TR200100254T TR200100254T2 TR 200100254 T2 TR200100254 T2 TR 200100254T2 TR 2001/00254 T TR2001/00254 T TR 2001/00254T TR 200100254 T TR200100254 T TR 200100254T TR 200100254 T2 TR200100254 T2 TR 200100254T2
Authority
TR
Turkey
Prior art keywords
poly
bacteria
fusible
lysine
polyester
Prior art date
Application number
TR2001/00254T
Other languages
English (en)
Inventor
Sang Park Johg
Choi Young-Hun
Sung Kim Wan
Original Assignee
Expression Genetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Expression Genetics, Inc. filed Critical Expression Genetics, Inc.
Publication of TR200100254T2 publication Critical patent/TR200100254T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B1/00—Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/66—Polyesters containing oxygen in the form of ether groups
    • C08G63/664—Polyesters containing oxygen in the form of ether groups derived from hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/68—Polyesters containing atoms other than carbon, hydrogen and oxygen
    • C08G63/685—Polyesters containing atoms other than carbon, hydrogen and oxygen containing nitrogen
    • C08G63/6852—Polyesters containing atoms other than carbon, hydrogen and oxygen containing nitrogen derived from hydroxy carboxylic acids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Polyamides (AREA)

Abstract

poli[alfa-(4-aminobutil)-L-glikolik asid], Bir genin bir hücreye iletilmesine uygun bir bakterilerle ayrisabilir terkip olarak açiklanmistir. PAGA'nin yapim ve kullanim yöntemi de açiklanmistir.
TR2001/00254T 1998-07-13 1999-07-13 Eriyebilir ve bakterilerle ayrışabilir bir gen iletim taşıyıcısı olarak poly-l-lysine benzeri bir poliyester. TR200100254T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9268298P 1998-07-13 1998-07-13

Publications (1)

Publication Number Publication Date
TR200100254T2 true TR200100254T2 (tr) 2001-06-21

Family

ID=22234532

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00254T TR200100254T2 (tr) 1998-07-13 1999-07-13 Eriyebilir ve bakterilerle ayrışabilir bir gen iletim taşıyıcısı olarak poly-l-lysine benzeri bir poliyester.

Country Status (15)

Country Link
US (1) US6217912B1 (tr)
EP (1) EP1117720A4 (tr)
JP (1) JP2002520435A (tr)
KR (1) KR20010079526A (tr)
CN (1) CN1313873A (tr)
AU (1) AU5100899A (tr)
BR (1) BR9912070A (tr)
CA (1) CA2337680A1 (tr)
FI (1) FI20010069A (tr)
HK (1) HK1041012A1 (tr)
IL (1) IL140785A0 (tr)
MX (1) MXPA01000271A (tr)
NO (1) NO20010201L (tr)
TR (1) TR200100254T2 (tr)
WO (1) WO2000002950A1 (tr)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2797652C (en) * 2000-07-21 2016-03-08 Revance Therapeutics, Inc. Multi-component biological transport systems
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
GB0103110D0 (en) * 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
US6939564B2 (en) 2001-06-08 2005-09-06 Labopharm, Inc. Water-soluble stabilized self-assembled polyelectrolytes
US7094810B2 (en) * 2001-06-08 2006-08-22 Labopharm, Inc. pH-sensitive block copolymers for pharmaceutical compositions
US7034037B2 (en) 2001-06-29 2006-04-25 Ethicon, Inc. Compositions and medical devices utilizing bioabsorbable polymeric waxes and rapamycin
US7030127B2 (en) 2001-06-29 2006-04-18 Ethicon, Inc. Composition and medical devices utilizing bioabsorbable polymeric waxes
US6967234B2 (en) 2002-12-18 2005-11-22 Ethicon, Inc. Alkyd-lactone copolymers for medical applications
CN1194704C (zh) * 2001-11-12 2005-03-30 华东理工大学 含有活性药物、主链中具有氨基酸的聚酯及其制备方法
US20030186916A1 (en) * 2002-03-12 2003-10-02 Lei Yu Vector for transfection of eukaryotic cells
US7005136B2 (en) 2002-03-29 2006-02-28 Ethicon, Inc. Bone replacement materials utilizing bioabsorbable liquid polymers
US7326426B2 (en) 2002-03-29 2008-02-05 Ethicon, Inc. Compositions and medical devices utilizing bioabsorbable liquid polymers
US7374930B2 (en) * 2002-05-21 2008-05-20 Expression Genetics, Inc. GLP-1 gene delivery for the treatment of type 2 diabetes
US7368125B2 (en) 2002-06-05 2008-05-06 Ethicon, Inc. Amphiphilic polymers for medical applications
US7026374B2 (en) 2002-06-25 2006-04-11 Aruna Nathan Injectable microdispersions for medical applications
US7101566B2 (en) 2002-06-28 2006-09-05 Ethicon, Inc. Polymer coated microparticles for sustained release
ES2347239T3 (es) * 2002-12-02 2010-10-27 Amgen Fremont Inc. Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
US6872799B2 (en) 2002-12-18 2005-03-29 Ethicon, Inc. Functionalized polymers for medical applications
US6866860B2 (en) 2002-12-19 2005-03-15 Ethicon, Inc. Cationic alkyd polyesters for medical applications
EP1599748A4 (en) * 2003-03-06 2007-10-24 John H Shadduck ADAPTIVE OPTICAL LENS AND METHOD OF MANUFACTURE
US7309757B2 (en) * 2003-06-20 2007-12-18 Agency For Science, Technology And Research Polymers for the delivery of bioactive agents and methods of their preparation
US7883720B2 (en) * 2003-07-09 2011-02-08 Wisconsin Alumni Research Foundation Charge-dynamic polymers and delivery of anionic compounds
US8092788B2 (en) * 2004-03-03 2012-01-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
PT1729821E (pt) 2004-03-03 2013-10-23 Revance Therapeutics Inc Composições e métodos para aplicação tópica e administração transdérmica de toxinas botulínicas
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
WO2006068232A1 (ja) 2004-12-22 2006-06-29 Sapporo Medical University 線維化抑制のための薬物担体および薬物担体キット
EP1861112A4 (en) * 2005-03-03 2009-07-22 Revance Therapeutics Inc COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF BOTULINUM TOXINS
WO2006113666A2 (en) * 2005-04-19 2006-10-26 Massachusetts Institute Of Technology Amphiphilic polymers and methods of use thereof
US20070031512A1 (en) * 2005-08-03 2007-02-08 Amcol International Corporation Virus-interacting layered phyllosilicates and methods of inactivating viruses
US20080184618A1 (en) * 2005-08-03 2008-08-07 Amcol International Virus-Interacting Layered Phyllosilicates and Methods of Use
US20100272769A1 (en) * 2005-08-03 2010-10-28 Amcol International Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use
NZ568216A (en) * 2005-11-17 2012-09-28 Revance Therapeutics Inc Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
FR2899231B1 (fr) * 2006-04-03 2008-09-05 Isochem Sa NOUVEAUX O-CARBOXY ANHYDRIDES (OCAs) A FONCTION SALIFIABLE ET POLYMERES OBTENUS A PARTIR DE CES OCAs
US8124598B2 (en) 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
BRPI0716890A2 (pt) * 2006-09-22 2013-10-22 Labopharm Inc Composição, e, método de produção de uma composição, de administração de um agente farmaceuticamente ativo insolúvel em água a um mamífero, e de tratamento de câncer em um mamífero
MX2009007070A (es) * 2006-12-29 2009-07-10 Revance Therapeutics Inc Moleculas de transporte que utilizan los polipeptidos hiv-tat de secuencia inversa.
US20080233152A1 (en) * 2006-12-29 2008-09-25 Revance Therapeutics, Inc. Compositions and Methods of Topical Application and Transdermal Delivery of Botulinum Toxins Stabilized with Polypeptide Fragments Derived from HIV-TAT
US8834918B2 (en) * 2007-01-22 2014-09-16 Wisconsin Alumni Research Foundation Modified multilayered film
TWI407971B (zh) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
US8481084B2 (en) * 2007-05-23 2013-07-09 Amcol International Corporation Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
CA2698812A1 (en) 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
US20090105375A1 (en) * 2007-10-09 2009-04-23 Lynn David M Ultrathin Multilayered Films for Controlled Release of Anionic Reagents
US8324333B2 (en) 2008-06-05 2012-12-04 Wisconsin Alumni Research Foundation Anionic charge-dynamic polymers for release of cationic agents
WO2010093452A2 (en) * 2009-02-11 2010-08-19 University Of Houston Reducible polymers for non-viral gene delivery
US8470891B2 (en) * 2009-12-23 2013-06-25 International Business Machines Corporation Biodegradable block polymers for drug delivery, and methods related thereto
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN104531671A (zh) 2010-10-01 2015-04-22 现代治疗公司 设计核酸及其使用方法
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3682905B1 (en) 2011-10-03 2021-12-01 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151666A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of biologics and proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243953A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of nuclear proteins
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
EP2946014A2 (en) 2013-01-17 2015-11-25 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
GB201304245D0 (en) * 2013-03-08 2013-04-24 Inst Quimic De Sarria Chemical compounds
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CA2917348A1 (en) 2013-07-11 2015-01-15 Moderna Therapeutics, Inc. Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CN106061466A (zh) 2013-12-19 2016-10-26 诺华股份有限公司 瘦蛋白mRNA组合物和制剂
EP3169693B1 (en) 2014-07-16 2022-03-09 ModernaTX, Inc. Chimeric polynucleotides
EP3171895A1 (en) 2014-07-23 2017-05-31 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
AU2015296861A1 (en) 2014-07-31 2017-02-16 The Board Of Regents Of The University Of Oklahoma High isomerohydrolase activity mutants of mammalian RPE65
CN105920618A (zh) * 2016-06-13 2016-09-07 上海交通大学医学院附属新华医院 一种生物靶向纳米基因材料及其制造方法
EP3612215A4 (en) 2017-04-20 2021-05-26 aTyr Pharma, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF Pneumonia
AU2018270111B2 (en) 2017-05-18 2022-07-14 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
US11485972B2 (en) 2017-05-18 2022-11-01 Modernatx, Inc. Modified messenger RNA comprising functional RNA elements
EP3638292A1 (en) 2017-06-14 2020-04-22 ModernaTX, Inc. Polynucleotides encoding coagulation factor viii
EP3679140B1 (en) 2017-09-08 2022-11-16 MiNA Therapeutics Limited Stabilized cebpa sarna compositions and methods of use
EP3714048A1 (en) 2017-11-22 2020-09-30 Modernatx, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
US20220265856A1 (en) 2017-11-22 2022-08-25 Modernatx, Inc. Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
JP7423521B2 (ja) 2017-11-22 2024-01-29 モダーナティエックス・インコーポレイテッド フェニルケトン尿症の治療用のフェニルアラニンヒドロキシラーゼをコードするポリヌクレオチド
EP3735270A1 (en) 2018-01-05 2020-11-11 Modernatx, Inc. Polynucleotides encoding anti-chikungunya virus antibodies
EP3775211B1 (en) 2018-04-12 2023-04-05 MiNA Therapeutics Limited Sirt1-sarna compositions and methods of use
WO2019226650A1 (en) 2018-05-23 2019-11-28 Modernatx, Inc. Delivery of dna
WO2020010107A1 (en) 2018-07-03 2020-01-09 Gilead Sciences, Inc. Antibodies that target hiv gp120 and methods of use
WO2020023390A1 (en) 2018-07-25 2020-01-30 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
JP2021534101A (ja) 2018-08-09 2021-12-09 ヴェルソー セラピューティクス， インコーポレイテッド Ｃｃｒ２及びｃｓｆ１ｒを標的とするためのオリゴヌクレオチド組成物ならびにその使用
EP3846776A1 (en) 2018-09-02 2021-07-14 ModernaTX, Inc. Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency
EP3849594A2 (en) 2018-09-13 2021-07-21 Modernatx, Inc. Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease
US20230009009A1 (en) 2018-09-13 2023-01-12 Modernatx, Inc. Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease
US20220401584A1 (en) 2018-09-14 2022-12-22 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
EP3856233A1 (en) 2018-09-27 2021-08-04 Modernatx, Inc. Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
WO2020208361A1 (en) 2019-04-12 2020-10-15 Mina Therapeutics Limited Sirt1-sarna compositions and methods of use
US20220226438A1 (en) 2019-05-08 2022-07-21 Astrazeneca Ab Compositions for skin and wounds and methods of use thereof
MX2021015452A (es) 2019-06-25 2022-02-11 Gilead Sciences Inc Proteinas de fusion flt3l-fc y metodos de uso.
WO2021011544A1 (en) 2019-07-16 2021-01-21 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
WO2021067181A1 (en) 2019-09-30 2021-04-08 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
CA3184474A1 (en) 2020-06-01 2021-12-09 Modernatx, Inc. Phenylalanine hydroxylase variants and uses thereof
EP3954393A1 (en) 2020-08-13 2022-02-16 Bioasis Technologies Inc. Combination therapies for delivery across the blood brain barrier
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US20230406895A1 (en) 2020-11-13 2023-12-21 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
WO2022204371A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
WO2022204370A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
WO2022204380A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
WO2022204369A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
WO2022204390A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
AU2022246144A1 (en) 2021-03-26 2023-09-21 Mina Therapeutics Limited Tmem173 sarna compositions and methods of use
EP4355882A2 (en) 2021-06-15 2024-04-24 Modernatx, Inc. Engineered polynucleotides for cell-type or microenvironment-specific expression
WO2022271776A1 (en) 2021-06-22 2022-12-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
WO2023056044A1 (en) 2021-10-01 2023-04-06 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
CN114452266B (zh) * 2022-02-09 2023-05-19 南京凯玛生物科技有限公司 一种基于重组核糖体蛋白的核酸药物递送系统及其制备方法和应用
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use
WO2023183909A2 (en) 2022-03-25 2023-09-28 Modernatx, Inc. Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
WO2024026254A1 (en) 2022-07-26 2024-02-01 Modernatx, Inc. Engineered polynucleotides for temporal control of expression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
AU1819499A (en) * 1997-12-12 1999-06-28 Samyang Corporation Positively-charged poly{alpha-(omega-aminoalkyl)glycolic acid} for the delivery of a bioactive agent via tissue and cellular uptake

Also Published As

Publication number Publication date
MXPA01000271A (es) 2002-10-17
US6217912B1 (en) 2001-04-17
CA2337680A1 (en) 2000-01-20
CN1313873A (zh) 2001-09-19
NO20010201L (no) 2001-03-12
IL140785A0 (en) 2002-02-10
FI20010069A (fi) 2001-03-09
EP1117720A1 (en) 2001-07-25
KR20010079526A (ko) 2001-08-22
WO2000002950A9 (en) 2000-07-20
WO2000002950A1 (en) 2000-01-20
HK1041012A1 (zh) 2002-06-28
JP2002520435A (ja) 2002-07-09
AU5100899A (en) 2000-02-01
NO20010201D0 (no) 2001-01-12
BR9912070A (pt) 2001-04-10
EP1117720A4 (en) 2001-11-14

Similar Documents

Publication Publication Date Title
TR200100254T2 (tr) Eriyebilir ve bakterilerle ayrışabilir bir gen iletim taşıyıcısı olarak poly-l-lysine benzeri bir poliyester.
EP1650193A3 (en) 6-Phenylphenanthridines with PDE-IV inhibiting activity
IL147564A0 (en) Neutral lipopolymer and liposomal compositions containing same
ATE237312T1 (de) In liposomen verkapselte nukleinsäurekomplexe
TR199901250T2 (tr) Tedavi amaçli ajanlar.
HK1034911A1 (en) Novel fatty acid analogues for the treatment of secondary restenosis
NZ336961A (en) Polymer blend comprising a polyester, a polyfunctional acid anhydride and a polyhydric alcohol
PL341711A1 (en) Laccase containing composition for oxidatingly dyeing creatine fibre and dyeing method employing such composition
CA2297911A1 (en) Substituted 6-phenylphenanthridines
EP1176210A4 (en) PREPARATION CONTAINING A CELL EXTRACT FOR PRODUCING A CELL-FREE PROTEIN AND DEVICE FOR PRODUCING A CELL-FREE PROTEIN
BR9910251A (pt) Estimulação hematopoiética
YU19499A (sh) Benzonaftiridini kao bronhijalni terapeutici
TR199801933A2 (tr) Biyolojik olarak tolare edilebilen düsük moleküler polietileniminler.
PL338339A1 (en) Novel derivatives of tetrazole
AU2904300A (en) Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity
WO2000016733A3 (en) Personal care compositions containing active proteins tethered to a water insoluble substrate
CA2269640A1 (en) Enzymatic cofactor cycling using soluble pyridine nucleotide transhydrogenase
TR200403501T2 (tr) Transgenik bitki ve metotları.
ATE226183T1 (de) Perowskit für eine beschichtung von interkonnektoren
GEP20063972B (en) Streptogramin derivatives, preparation and compositions containing them
PT1147087E (pt) Feantridina-n-oxidos com actividade de inibicao de pde-iv
BG104396A (en) New carboxylic acid derivatives, carrying amido side-chains, production and use as endothelin receptor antagonists
TR200401462T4 (tr) Torsemid modifikasyonu II' yi içeren dengeli bir farmasötik formülasyonu
GB2341782A (en) Environmentally friendly chewing gum bases
HUP0102413A1 (hu) Vektorok nukleinsavak bevitelére, ezeket tartalmazó készítmények és alkalmazásuk